Related Experiment Video

Updated: May 22, 2026

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

Recent advances and novel agents for gastrointestinal stromal tumor (GIST)

Gurpreet Lamba1, Samir Ambrale, Byung Lee

  • 1Division of Oncology/Hematology, New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USA.

Journal of Hematology & Oncology
|May 10, 2012
PubMed

Insights

The discovery of CD117 mutations revolutionized gastrointestinal stromal tumor (GIST) treatment. This review highlights recent advances and novel targeted therapies for GIST, improving patient outcomes.

Area of Science:

  • Oncology
  • Molecular Pathology
  • Gastroenterology

Background:

  • CD117 mutations are nearly universal in gastrointestinal stromal tumors (GISTs).
  • Most other GI spindle cell neoplasms are CD117-negative, aiding GIST diagnosis.
  • GIST research exemplifies successful targeted therapy development.

Purpose of the Study:

  • To review recent advancements in GIST therapy.
  • To discuss novel therapeutic agents for GIST treatment.

Main Methods:

  • Literature review of recent GIST research and clinical trials.
  • Analysis of molecular pathogenesis and targeted therapy strategies.

Main Results:

  • CD117 mutation discovery is a key diagnostic and therapeutic marker for GIST.
  • Targeted therapies inhibiting specific molecular pathways show high efficacy.
  • Ongoing investigations explore new treatment modalities for GIST.

Conclusions:

  • Targeted inhibition of GIST driver pathways has dramatically improved clinical outcomes.
  • Novel agents and strategies are under development to further enhance GIST treatment.
  • The paradigm of molecularly targeted therapy is highly effective for GIST.

More Related Videos

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD: